In the life sciences space, its hard to avoid dealing with regulators. Yet, getting your product developed and marketed depends on successful regulatory interactions. Right now, many accuse the FDA of being particularly conservative. Leran about the current FDA environment and what different companies, both within the biopharma and device space are doing to advance their programs, in some cases with unique approaches which may minimize the impact of the FDA.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…